tldrdailynews.com logo

"Viking Therapeutics' Weight-Loss Drug Sparks Stock Surge"

1 min read
Source: Financial Times
TL;DR

Viking Therapeutics' shares more than doubled after the biopharmaceutical company announced "statistically significant" results from a weight-loss trial. The positive outcome of the trial led to a surge in the company's stock, reflecting investor optimism about the potential of its treatment.

Topics:businessfinance#biopharmaceutical#finance#shares#stock-market#viking-therapeutics#weight-loss-trial
Share this article
  1. Viking Therapeutics shares more than double on 'statistically significant' weight-loss trial results  Financial Times
  2. Experimental weight-loss drug from Viking Therapeutics could rival Ozempic, Mounjaro  The Washington Post
  3. Ozempic, Wegovy competitor drug doubles Viking Therapeutics stock  Quartz
  4. Viking's GLP-1 spurs steep weight loss, sending shares up 80%  Fierce Biotech
  5. Viking Catapults As Weight-Loss Drug Beats Lilly's Zepbound  Investor's Business Daily

Want the full story? Read the original reporting

Read on Financial Times